@manjuggm @pashtoonkasi @jonathanloree @IbrahimSahinMD1 Also with 5-FU. Confirmed on FDA/ASHP shortage websites…
English
Daniel Ahn
706 posts
@manjuggm @pashtoonkasi @jonathanloree @IbrahimSahinMD1 Not a rumor, there is a national shortage. We were informed several weeks ago, specifically in 500mg tabs.
English
Hearing rumors of a capecitabine shortage.. Can someone give more details? How bad is it? How long is it likely to last? Thanks!
#GIOncology @pashtoonkasi @jonathanloree @IbrahimSahinMD1
English
@DucreuxMichel pubmed.ncbi.nlm.nih.gov/30508156/ . @KoheiShitara REVERCE2 ongoing to confirm findings in US patients. 3. Similar studies have shown similar OS results . BACCI (jamanetwork.com/journals/jaman…) @GIcancerDoc . 4. Why was SOLSTICE negative? TAS102/bev vs cape?
English
@DucreuxMichel After having time to think about the results, don’t believe the hype. The discussant failed to mention 3 key points. 1. Is this a bev naive effect (~30% had no prior bev exposure). 2 is this a sequencing effect? Rego has shown better OS when given in third line therapy (1/3)
English
NAPOLI-3 positive. Historical retrospective data suggests no difference in survival between FOLFIRINOX and gem abraxane. Maybe naliri isn’t the same as iri? Looking forward to see data. @GIcancerDoc ipsen.com/us/blog/press-…
English
It was awesome sharing the stage with #PancreaticCancer superstar @KReissMD in Orlando at APA meeting … made some friends 🐊 along the way … missed @EileenMOReilly by 2 days although had the opportunity to connect with her in Chicago @ALLIANCE_org meeting !
English
Trade: Detroit is dealing TE T.J. Hockenson in its division, to the Minnesota Vikings, per sources.
English
@R_Brauninger That’s the take home? Should be: 1. O line is terrible, Aki needs to take a seat permanently on the bench. 2. Jimbo needs an OC and 3. Jimbo needs an OC. Play call, time management (wasted two timeouts in the second half).
English
Kids played extremely hard. A bunch of those young kids grew up a lot tonight.
Let’s see what happens in a couple of weeks.
English
Glad to see that Dr. @Jcj84Jeremy now has a site open for OBERTO 301 in Jacksonville, FL
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
NCT05243862
clinicaltrials.gov/ct2/show/NCT05…
English
"Of the 5 patients who received at least 2-doses of the vaccine, 3 experienced Stable Disease & 2 had unexpected tumor size reduction of whom one patient experienced complete tumor shrinkage on two of three target lesions & partial response on one lesion."
precisionvaccinations.com/treos-bio-poly…
A.n.n.@fireflyann
Counting down My Top 10 Clinical Trials of 2018. OBERTO a Phase 1 trial - PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer. Opened w/ 10 spots, expanded to 15. #CRCtrials #CRCSM #colorectal clinicaltrials.gov/ct2/show/NCT03…
English
Thank you for the opportunity to speak at this event for this great endeavor! @GIcancerDoc @MayoCancerCare
A.n.n.@fireflyann
Next up at @KRASKickers Connect Patient conference today. Targeting KRAS: From the “Undruggable” to Druggable in Colorectal Cancer Daniel Ahn, D.O. , M.S. , Mayo Clinic @the_danielahn @MayoClinic
English
As an oncology fellow, I got used to friday 5pm acute leuk consults. This past Friday was much happier trip to the hospital. Introducing Nadeem Alexander Jurdi 👶😍
English
@MarkYarchoan @graokane Sounds like from the press release, PFS was also missed which cannot be attributed to second line ICIs. It will be interesting to see the data.
English
@GABOUALFA Thanks Ghassan. Disappointing but not shocking. Landscape is becoming clearer for first line. “Line minus one is now line none.”
English
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma did not meet primary OS - businesswire.com/news/home/2022…
English
@Amitmahipal79 @MayoCancerCare @UHhospitals @jorgegarcia @TedTeknosMD @doctorC369 Congrats Amit and Sakti!
Deutsch
Daniel Ahn nag-retweet
@the_danielahn @DrChowdharyMD @SprakerMDPhD @freddyeescorcia @chadinabhan @MayoCancerCare @rweichselbaum @jmmrad @subatomicdoc @MikeChuongMD @JoeHermanMD @olusolaodavies @KrishanJethwa @RadDocMReyngold “Given that olaparib is expensive and relatively toxic, and in the absence of a clear survival benefit, it may be difficult to justify its use”
English
Concise and excellent editorial by @GIcancerDoc & @the_danielahn from @MayoCancerCare on the role of RT in non-metastatic pancreatic cancer.
Appears it should not be given unless part of a study. @rweichselbaum @freddyeescorcia @jmmrad @subatomicdoc
jamanetwork.com/journals/jamao…
English
Daniel Ahn nag-retweet
It is time we started treating radiation as experimental therapy in pancreatic cancer and found a way to prove its utility. I still use it where I believe it helps--such things as clearing margins and getting people time off systemic therapy, but would be nice to prove benefit
Tanios Bekaii-Saab, MD@GIcancerDoc
"In conclusion, there is very little evidence to support the use of radiotherapy in nonmetastatic #pancreaticcancer. Further exploratory studies may define a role in a select subgroup of patients with borderline resectable and locally advanced disease ...."
English
@the_danielahn @GIcancerDoc I see.
Thank you very much Mr. Elon Musk for the timely unblocking.
Dallas, TX 🇺🇸 English
"In conclusion, there is very little evidence to support the use of radiotherapy in nonmetastatic #pancreaticcancer. Further exploratory studies may define a role in a select subgroup of patients with borderline resectable and locally advanced disease ...."
Daniel Ahn@the_danielahn
Our editorial on A021501. Do we really need radiation in PDAC? Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer | Gastroenterology | JAMA Oncology | JAMA Network @MayoCancerCare @GIcancerDoc jamanetwork.com/journals/jamao…
English
